Home > Boards > US Listed > Biotechs > NanoViricides Inc. (NNVC)

Ansun BioPharma Announces Breakthrough Designation for its Experimental

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Rawnoc Member Profile
 
Followed By 1,149
Posts 139,854
Boards Moderated 4
Alias Born 08/27/03
160x600 placeholder
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 3/24/2020 5:02:45 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/20/2020 3:15:50 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 2/19/2020 6:04:12 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 2/14/2020 5:54:58 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/11/2020 4:31:30 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 2/5/2020 4:22:04 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/28/2020 6:11:41 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/27/2020 5:12:40 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 1/27/2020 12:12:19 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/24/2020 4:13:38 PM
Prospectus Filed Pursuant to Rule 424(b)(1) (424b1) Edgar (US Regulatory) - 1/24/2020 6:03:05 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 1/10/2020 6:01:05 AM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 1/8/2020 5:15:55 PM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 1/7/2020 6:02:23 AM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 1/2/2020 12:40:33 PM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 12/23/2019 12:52:29 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/19/2019 4:47:27 PM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 12/17/2019 6:03:27 AM
Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp) Edgar (US Regulatory) - 12/17/2019 6:02:51 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/13/2019 5:20:46 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/15/2019 5:27:01 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 11/14/2019 1:55:53 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/6/2019 6:05:48 AM
Withdrawal of Registration Statement (rw) Edgar (US Regulatory) - 11/6/2019 6:04:59 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 10/28/2019 5:03:25 PM
Rawnoc   Thursday, 11/16/17 06:12:55 PM
Re: KMBJN post# 136115
Post # of 143225 
Ansun BioPharma Announces Breakthrough Designation for its Experimental Drug DAS181

https://www.prnewswire.com/news-releases/ansun-biopharma-announces-breakthrough-designation-for-its-experimental-drug-das181-300533677.html?tc=

"Ansun recently completed a Phase 2 study of DAS181 for treatment of PIV infection in hospitalized, immunocompromised patients and is now in the planning stage of a Phase 3 study. In addition, Ansun has worked in collaboration with the FDA to make DAS181 available for treatment of over 130 pediatric and adult patients through compassionate use under single patient emergency IND applications. "We are excited about this designation and look forward to continuing to work closely with the Division of Antiviral products at the FDA as we plan and implement a Phase 3 study for this severely ill patient population," said Dr. George Wang, Chief Technical Officer of Ansun Biopharma."




The SwingTrade Portfolio is up 25.2% YTD and 539% since inception.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=124500405
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist